Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments is positioned for strong growth in the coming years, driven by its unique healthcare technology platform, Clover Assistant, which empowers Medicare physicians to proactively manage chronic diseases. The company's robust membership growth, with a strong base of returning members and high retention rates, is a testament to Clover's ability to profitably onboard new members in a competitive market. The company's focus on markets where it has a strong presence and high adoption of Clover Assistant, along with its strong financial performance and favorable rates, gives us confidence in Clover's ability to deliver in the future. However, there are potential risks, such as liquidity concerns, regulatory changes, and competition in the Medicare Advantage market, that could impact the company's financial performance. Overall, we believe Clover Health Investments has a solid foundation for sustained growth and profitability, and we maintain a positive outlook on the stock.

Bears say

Clover Health Investments is facing a combination of headwinds in 2027, including being paid as a 3.5-star plan and flat CMS MA advance rates. Management remains confident in its ability to manage medical costs through technology, but there is potential for negative surprises in these areas. Additionally, potential regulatory changes and competition could impact the company's profitability and outlook. While the company has shown impressive membership growth and profitability in 2025 and expects to achieve GAAP net income in 2026, there is still uncertainty surrounding its projections and potential risks.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.